Initial therapy of choice for PRL-PAs consists, usually, of dopamine agonists, while other pituitary tumors are addressed by transsphenoidal surgery and subsequent pharmacological therapy with somatostatin analogs (SSAs) and dopamine agonists, or radiotherapy for resistant or metastatic tumors [1,4,6]. This evidence concerns the gene PRL and pituitary tumor.